This will be a long-term multi-center study to comprehensively study patients with primary liver cancer (PLC).
Principal Investigator
Sukeshi Arora
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
Patients with histologically/ultrasound/imaging confirmed or suspicious lesions of HCC or CCA.
Patients with planned or a history of at least 1 dose of immunotherapy for HCC or CCA.
Ability of subject to understand and the willingness to sign a written informed consent document.
Age > 18 years old at date of study consent
Patients with known HIV infection as these patients may have abnormal test results which may confound the endpoints of this study